Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACYW vs Nimenrix 1+1 schedule in infants
2023-508177-85-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of meningococcal A conjugate vaccine in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoints: Geometric mean titers (GMTs) of antibodies against meningococcal serogroups A, C, W and Y and Vaccine seroresponse to meningococcal serogroups A, C, W and Y assessed by hSBA. Started Mar 2024; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2023-508177-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508177-85-00.